Subodh Verma, MD, of St. Michael’s Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART Cardiolink-6 study, the first randomized, double-blind trial investigating the effect of empagliflozin on LV structure and function in patients with type 2 diabetes and established cardiovascular disease. Dr. Verma presented the results of EMPA-HEART Cardiolink-6 at the American Heart Association 2018 Scientific Session.
Researchers included a total of 152 individuals with type 2 diabetes and a prior history of MI or coronary revascularization in the study. Participants were randomized (1:1) to receive either empagliflozin 10 mg or placebo for six months. The primary endpoints included changes in indexed LV end-systolic/diastolic volumes, LV ejection fraction, regional LV systolic/diastolic function, NT-proBNP, and troponins.
Read DocWire News’ coverage of EMPA-HEART Cardiolink-6 here.
Read more DocWire News coverage of AHA 2028 here.